|
|
Vaccine Detail
|
Qβ-MUC1-β-Tf Conjugate Vaccine |
| Vaccine Information |
- Vaccine Name: Qβ-MUC1-β-Tf Conjugate Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Type: Conjugate vaccine
- Status: Research
- Host Species for Licensed Use: Mouse
- Antigen: MUC1 (Wu et al., 2021)
-
Adjuvant:
MPLA (Wu et al., 2021)
- Immunization Route: subcutaneous injection
- Description: A synthetic glycopeptide-VLP conjugate vaccine containing a MUC1 glycopeptide bearing an unnatural beta-linked Thomsen-Friedenreich (Tf) disaccharide [(beta)Gal-(1,3)-(beta)GalNAc] covalently conjugated to bacteriophage Q(beta) virus-like particles (~220 glycopeptides per capsid), with potential antineoplastic activity. The unnatural beta-glycosyl linkage provides significantly enhanced stability toward glycosidase degradation (no detectable cleavage after 24 hours versus near-complete cleavage of the natural alpha-linked MUC1-Tf glycopeptide within 1.75 hours). Vaccination with Q(beta)-MUC1-(beta)-Tf conjugate with MPLA adjuvant successfully overcame MUC1 immune tolerance in human MUC1 transgenic mice, inducing high IgG antibody titers (mean 2,200,000 ELISA units, >1,000-fold over control) encompassing all major IgG subtypes with both Th1 and Th2 activation. The induced antibodies demonstrated complement-mediated cytotoxicity toward MUC1-expressing melanoma tumor cells equivalent to those induced by the natural MUC1-alpha-Tf vaccine. MUC1 antigen, a membrane-bound glycoprotein overexpressed in aberrant or hypoglycosylated form in multiple cancers including breast, lung, pancreatic, colon, prostate, and ovarian cancers (Wu et al., 2021).
|
| Host Response |
|
|
| References |
Wu et al., 2021: Wu X, McFall-Boegeman H, Rashidijahanabad Z, Liu K, Pett C, Yu J, Schorlemer M, Ramadan S, Behren S, Westerlind U, Huang X. Synthesis and immunological evaluation of the unnatural β-linked mucin-1 Thomsen-Friedenreich conjugate. Organic & biomolecular chemistry. 2021; 19(11); 2448-2455. [PubMed: 33645601].
|
|
